It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Endothelial cells play a key role in the regulation of disease. Defective regulation of endothelial cell homeostasis may cause mesenchymal activation of other endothelial cells or neighboring cell types, and in both cases contributes to organ fibrosis. Regulatory control of endothelial cell homeostasis is not well studied. Diabetes accelerates renal fibrosis in mice lacking the endothelial glucocorticoid receptor (GR), compared to control mice. Hypercholesterolemia further enhances severe renal fibrosis. The fibrogenic phenotype in the kidneys of diabetic mice lacking endothelial GR is associated with aberrant cytokine and chemokine reprogramming, augmented Wnt signaling and suppression of fatty acid oxidation. Both neutralization of IL-6 and Wnt inhibition improve kidney fibrosis by mitigating mesenchymal transition. Conditioned media from endothelial cells from diabetic mice lacking endothelial GR stimulate Wnt signaling-dependent epithelial-to-mesenchymal transition in tubular epithelial cells from diabetic controls. These data demonstrate that endothelial GR is an essential antifibrotic molecule in diabetes.
The endothelial glucocorticoid receptor plays a key role in the regulation of many diseases, including diabetes. Loss of this receptor results in accelerated renal fibrosis, a heightened inflammatory milieu, augmented Wnt signaling and suppression of fatty acid oxidation in diabetic kidneys.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Yale University School of Medicine New Haven, Department of Pediatrics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine New Haven, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Kanazawa Medical University, Department of Diabetology and Endocrinology, Uchinada, Japan (GRID:grid.411998.c) (ISNI:0000 0001 0265 5359)
2 Yale University School of Medicine New Haven, Department of Pediatrics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine New Haven, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
3 Yale University School of Medicine New Haven, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine New Haven, Department of Surgery, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
4 Kanazawa Medical University, Department of Diabetology and Endocrinology, Uchinada, Japan (GRID:grid.411998.c) (ISNI:0000 0001 0265 5359)
5 Yale University School of Medicine New Haven, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine New Haven, Department of Surgery, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); VA Connecticut Healthcare System, Department of Surgery, West Haven, USA (GRID:grid.281208.1) (ISNI:0000 0004 0419 3073)
6 Yale University School of Medicine New Haven, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine New Haven, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine New Haven, Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM), New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine New Haven, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)